Newsroom press releases

15/12/23 - 17:38

Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)

Financial Data

03/11/23 - 15:51

Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)

Financial Data

27/07/23 - 13:18

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)

Financial Data

26/05/23 - 7:10

DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)

Acquisition / Partnership

09/05/23 - 11:56

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)

Financial Data

27/03/23 - 14:38

Dividend coupon date correction (493.46 KB)

Financial Data

27/03/23 - 13:35

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)

Financial Data

28/02/23 - 16:06

Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)

Acquisition / Partnership

13/02/23 - 22:03

CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)

Acquisition / Partnership